2 min read

Piramal Pharma Moat Analysis: Score & Risks

Moat Note · First-pass

Piramal Pharma Ltd.

A first-pass moat teardown of Piramal Pharma Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
5.28 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Intangible Assets. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Piramal Pharma Ltd. scores 5.28 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D5Intangible Assets6
M · Mechanism Verified verbatim

“our brand Gablofen ranks as the number one brand in the US market in the Baclofen pre-filled syringe and vial category.”

Piramal Pharma Ltd. · Annual Report · p.10
D1Network Effects5.7
M · Mechanism Verified verbatim

“The Company has 100% tech-enabled sales coverage and leverages analytics to enhance the productivity of its field force.”

Piramal Pharma Ltd. · Annual Report · p.22
D3Cost Advantage5.7
M · Mechanism Verified verbatim

“Solvent recovery improvement to generate savings of H 5.65 Crores by utility upgradation and Loss reduction.”

Piramal Pharma Ltd. · Annual Report · p.61
D6Efficient Scale5.7
M · Mechanism Verified verbatim

“These are all facilities that are generally capacity constrained, and these are all facilities that generally serve on-patented client work.”

Piramal Pharma Ltd. · Earnings Call · p.16
D2Switching Costs5.5
M · Mechanism Verified verbatim

“Partner with customers as 35+ Phase III projects transition development to registration to commercial”

Piramal Pharma Ltd. · Annual Report · p.24
D4Price Discretion5.5
M · Mechanism Verified verbatim

“undertaking judicious price increases where there is high price elasticity”

Piramal Pharma Ltd. · Annual Report · p.33
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?6.0
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?5.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 5 — below 6, so the band is capped narrow. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.